PLA2G7 and Alzheimer disease: In regard to clinical applications of Lp-PLA2 inhibitors, although some studies found Lp-PLA2 to be independently associated with AD and increased the risk of AD (38), clinical trials with darapladib, the most advanced Lp-PLA2 inhibitor, failed in 2 phase III trials (39, 40).